OpenAI and the FDA Are Holding Talks About Using AI In Drug Evaluation
1 min read
Summary
The US Food and Drug Administration (FDA) has been meeting with OpenAI to discuss using artificial intelligence (AI) to speed up the drug approval process, according to sources with knowledge of the meetings.
Marty Makary, FDA commissioner, wrote on X that they had just completed their first AI-assisted scientific review and that “that’s just the beginning”.
It is believed that OpenAI’s team has met with the FDA multiple times in recent weeks to discuss a project called cderGPT, which is likely to stand for Centre for Drug Evaluation and Research GPT.
While no contract has been signed, the FDA has also appointed its first-ever AI officer, Jeremy Walsh, who has met with acting chief AI officer at the Department of Health and Human Services, Peter Bowman-Davis, to discuss the FDA’s AI ambitions.
Robert Califf, who served as FDA commissioner until January, said the agency had been considering the various ways AI could be used in its internal operations.
Using AI to assist in drug reviews would represent just a small part of the drug development timeline.
